Ewa Gogola
Postdoctoral Researcher and Rubicon Fellow
I joined the Patel lab after completing my PhD at the Netherlands Cancer Institute in Amsterdam, the Netherlands, where I studied PARP inhibitor resistance in BRCA1/2-deficient cancers, under the supervision of Sven Rottenberg, Jos Jonkers and Piet Borst. I am currently a NWO Rubicon Fellow investigating tissue-specific responses to endogenous DNA damage and their contributions to tissue homeostasis and ageing.
Recent publications
-
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Journal article
Gogola E. et al, (2019), Annual Review of Cancer Biology, 3, 235 - 254
-
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Journal article
Gogola E. et al, (2018), Cancer Cell, 33, 1078 - 1093.e12
-
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Journal article
Barazas M. et al, (2018), Cell Rep, 23, 2107 - 2118
-
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
Journal article
Meghani K. et al, (2018), Cell Reports, 23, 100 - 111
-
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
Journal article
Duarte AA. et al, (2018), Nature Methods, 15, 134 - 140